Argentina surrogacy: medical and donor requirements
The short answer
Argentina has binding rules for medically assisted reproduction (MAR), authorised facilities, informed consent, donor-gamete banks, records and certain safety procedures. The primary sources do not establish a separate, exhaustive statutory medical checklist for a person acting as a gestational carrier in a surrogacy arrangement. A clinic may apply clinical criteria under its professional protocols, but those criteria must not be presented as if every one were a national statutory rule.
The distinction matters in practice: ask the clinic to identify the legal provision for each claimed “requirement”, and separately provide its written medical protocol. This article concerns medical and gamete conditions, not a general approval of surrogacy, a guarantee of treatment, or a determination of parentage. The position below is based on official material; local implementation and later changes still need professional review.
What the national framework covers
Law 26,862 and Decree 956/2013 regulate access to and delivery of assisted-reproduction techniques, including procedures using donor gametes or embryos. Resolution 1305/2015 sets authorisation and inspection standards for reproductive-medicine establishments and gamete banks. The Civil and Commercial Code, especially articles 560–564, governs informed consent and certain consequences of third-party gametes. These instruments apply to MAR generally; they do not amount to a complete surrogacy statute setting out every eligibility condition for the gestational carrier, intended parents and donors.
The legal gap must be described carefully. The absence of a dedicated surrogacy statute does not mean that clinics may ignore general health, licensing, consent, data-protection or reproductive-law requirements. Conversely, the fact that IVF or donor treatment is regulated does not, by itself, settle whether a particular surrogacy arrangement can proceed or how parentage will be recorded.
Use an authorised reproductive facility
Law 26,862 provides that assisted-reproduction procedures may be performed only by authorised healthcare establishments meeting the competent authority’s requirements. Resolution 1305/2015 details standards for facilities and banks, including responsible medical and technical personnel, written laboratory procedures, safety controls, quality assurance and records. A website or commercial promise does not prove current authorisation.
Before paying or starting medication, request the facility’s full legal name, authorisation details, registration entry and the responsible medical director’s identity. Confirm these with the competent national or provincial health authority, because the oversight route may depend on the facility and jurisdiction. Check the separate status of any sperm or oocyte bank used.
Informed consent must be documented
Civil and Commercial Code article 560 requires the treating health centre to obtain prior, informed and free consent from people undergoing MAR. Consent must be renewed whenever gametes or embryos are used. Article 561 addresses the required form and later notarisation or certification by the competent health authority. National programme guidance describes the usual revocation timing: before insemination in low-complexity treatment and before embryo transfer in high-complexity treatment. Confirm the exact point for the procedure.
Consent does not replace a lawful medical process or a surrogacy agreement. Ask for separate, clear documents identifying the technique, risks, alternatives, use of each person’s gametes, storage and future use of embryos, data handling, and the rights of the person carrying the pregnancy. The carrier and intended parent or parents need independent explanation of the legal consequences; a clinic form does not resolve parentage.
Specific rule for cryopreserved donor sperm
Resolution 1305/2015 contains an express safety rule for cryopreserved semen held by a sperm bank. The sample must remain in quarantine for the safety period required by the evaluation method. At the end of that period, the donor must be retested for HIV-1, HIV-2, hepatitis B and hepatitis C. The semen may be released for use only if those tests are negative. During quarantine, the storage system must prevent possible contamination of other samples.
The resolution does not set one universal number of quarantine days in the cited provision; it links the period to the method used for evaluation. Do not accept an invented “mandatory six months” or other fixed period without a source for the particular protocol. Request the laboratory’s documented release criteria, test dates and results, quarantine record, sample identifier and confirmation that the sample was released for clinical use.
Oocyte donors: clinical assessment and a key limit
Resolution 1305/2015 requires an oocyte bank’s procedures manual to describe the method used for clinical assessment of the donor. It also assigns the medical director responsibility for donor selection and supervision, and requires traceability records linking donors, oocytes, recipients and outcomes. The bank must maintain written protocols, quality controls and storage records.
In the text, the resolution does not provide the same explicit list of repeat HIV-1, HIV-2 and hepatitis B/C tests for oocyte donors that it expressly gives for cryopreserved semen. That is a limit of the cited text, not proof that no other applicable rule or medical standard exists. Ask the clinic to provide its current oocyte-donor screening protocol, including infectious-disease and genetic assessment where used, the clinical rationale, who approves eligibility, and the legal or professional source for any claimed mandatory test.
Donor source, payment and sample transport
Under Decree 956/2013, where donated gametes or embryos are required for treatment, they must come from gamete or embryo banks registered in the Federal Registry of Health Establishments (ReFES). If the donation took place at an establishment different from the one performing treatment, the decree requires an original sworn declaration from the receiving establishment confirming that the donor’s consent was duly obtained. The decree also states that gamete and embryo donation must never be lucrative or commercial.
These rules are not a complete answer to every payment question in a surrogacy programme. Do not automatically treat the rule on non-commercial donation as deciding whether particular gestational-carrier expenses or other payments are lawful; those arrangements need separate legal analysis. For gametes moved between facilities, Resolution 1305/2015 refers to applicable biological-sample transport rules and requires the movement to be documented, including departure and arrival times and the responsible parties. Cross-border import or export needs separate confirmation.
Age limits: do not apply them mechanically to a carrier
Resolution 1044/2018 states that MAR treatment using a woman’s own oocytes is to be provided up to age 44, unless a medical prescription indicates otherwise. Treatment using donated oocytes is to be provided up to age 51. A woman aged 44 to 51 may use her own oocytes cryopreserved before she turned 44. These are national treatment rules and are reflected in the Ministry of Health’s public guidance.
The resolution does not expressly explain how its wording applies when the person receiving the embryo is a gestational carrier and the oocytes belong to an intended parent or a third-party donor. Do not present “44/51” as a settled, surrogacy-specific age limit for the carrier without confirming the legal and clinical interpretation for that exact arrangement. Ask the clinic to identify the patient to whom it applies the rule, the relevant egg source, any medical exception, and the written authority for its decision.
Carrier and intended-parent medical screening
The national instruments reviewed set general standards for authorised MAR services and donor-bank procedures, but they do not supply one complete nationwide surrogacy-specific checklist covering a carrier’s prior pregnancies, age, body-mass index, obstetric history, mental-health assessment, or every medical contraindication. Such matters may be assessed under clinical judgment, evidence-based practice, facility protocols and local rules. The fact that a clinic uses a threshold does not by itself prove that the threshold appears in a national statute.
Request a written screening pathway for the gestational carrier and intended parent or parents: medical history, examination, pregnancy-related risk assessment, infection testing, medication review, psychological or counselling support if required by the protocol, and the criteria for declining or pausing treatment. Ask which items are legal obligations, which are professional standards, and which are that clinic’s own policy. A medical opinion should explain individual risks; a legal opinion should assess whether the proposed process can lawfully proceed.
Records, traceability and quality control
Resolution 1305/2015 requires donor banks to keep traceability records and duplicated records of donors, sample destinations, recipients and results. It also requires procedures for clinical donor assessment, sample identification, storage, freezing and thawing, and quality assurance. For oocytes, records link donors, the destination of the oocytes, recipients and outcomes. These are operational safeguards, not merely optional paperwork.
Ask for written confirmation of how each sperm sample, oocyte and resulting embryo is identified and tracked; where material is stored; how it is segregated during quarantine; how consent is linked to each use; and what happens if a test, label or record is missing. If material is transferred to another facility, obtain the transport record and confirm responsibility at each handover. If gametes are coming from abroad, do not ship them until the clinic and relevant authority confirm the current import, export and transport requirements.
Privacy and information about the donor
Donor and treatment records contain sensitive medical and reproductive information. Resolution 1305/2015 refers to the personal-data framework and requires traceability, while Law 25,326 treats health information as sensitive personal data. The clinic should explain who can access records, how samples and records are coded, how information is protected, and how long records are retained under applicable rules.
Do not promise that a donor is absolutely anonymous. Civil and Commercial Code articles 563–564 require information about third-party gametes to be recorded in the birth-registration file and allow a person born through MAR to obtain medically relevant donor information. A donor’s identity may be disclosed for duly founded reasons assessed by a court. The child’s future access rights and the clinic’s current privacy obligations must be addressed together, not reduced to a marketing label such as “anonymous donor”.
Clinical compliance does not settle parentage
Medical authorisation and correct use of gametes do not guarantee legal parentage registration. Under article 562 of Argentina’s Civil and Commercial Code, a child born through MAR is generally the child of the person who gives birth and the person who gave prior informed consent, regardless of who supplied the gametes. In “S., I. N. y otro c/ A., C. L.” (22 October 2024), a Supreme Court majority rejected a request to remove the gestational carrier from legal parentage; one justice dissented. By contrast, the National Civil Appeals Chamber, Sala H, declared article 562 unconstitutional in the specific BER case on 27 November 2025; a Neuquén family court did so in a specific pre-transfer case and authorised embryo transfer on 15 October 2026.
These are case-specific rulings with different facts and procedural postures; the lower-court decisions do not invalidate article 562 nationwide or establish a uniform route. They do not set medical eligibility criteria. Before embryo transfer, ask Argentine family-law counsel whether advance proceedings are available or advisable locally, what relief can be sought before birth, and what may remain unresolved after birth. Keep parentage separate from clinical eligibility.
Practical checklist before treatment
Before signing or paying, request a written answer tailored to the case. Obtain at least: (1) proof of the clinic’s current authorisation and registration; (2) registration details for each donor bank; (3) the donor-screening and sample-release protocol, with test dates and results where available; (4) medical-screening criteria for the carrier and intended parent or parents; (5) the applicable age rule and any documented medical exception; and (6) consent forms for each participant and each planned use of gametes or embryos.
Also request the traceability plan, storage and transfer records, privacy notice, donor-information policy, itemised clinical costs, and written basis for any restriction described as “required by law”. For each disputed condition, ask for the exact provision or professional standard and whether it is instead internal policy. Before the first transfer, have Argentine counsel verify current national and local rules and the parentage route. This checklist does not replace individual medical advice or a legal opinion.
How to classify a claimed requirement
Use the following matrix when a clinic says that a medical or donor condition is “mandatory”. It separates obligations expressly found in the sources from matters that need a clinic protocol or further legal confirmation. “Not specified in the cited rule” does not mean “forbidden” or “not medically necessary”; it means the provider should identify another valid source or explain that it is applying a clinical policy.
| Area | What the checked rule says | What to obtain or verify |
|---|---|---|
| Clinic | Only authorised facilities; Resolution 1305/2015 sets facility and bank standards. | Current authorisation, registration and responsible medical director. |
| Cryopreserved donor sperm | Quarantine; repeat HIV-1/2 and hepatitis B/C tests; release only after negative results. | Test dates/results, quarantine and release records; no fixed number of days in the cited clause. |
| Oocyte donor | Clinical-assessment method, donor selection and traceability are required; the same express repeat-test list is not stated in the cited text. | Current donor protocol and source for each test called mandatory. |
| Carrier age and health | No exhaustive surrogacy-specific checklist has been published; how the age rule applies needs case-specific confirmation. | Written clinical criteria and legal reasoning for the exact gamete/transfer arrangement. |
Primary legal and official sources
A source list is not a substitute for checking the current consolidated text and local implementation.
- Ley 26.862 — Acceso integral a los procedimientos y técnicas médico-asistenciales de reproducción médicamente asistida
- Decreto 956/2013 — Reglamentación de la Ley 26.862
- Resolución 1305/2015 — Normas de habilitación y fiscalización de establecimientos de reproducción médicamente asistida
- Código Civil y Comercial de la Nación — texto actualizado
- Resolución 1044/2018 — límites de edad para tratamientos de reproducción médicamente asistida
- Ministerio de Salud — Coordinación de Reproducción Médicamente Asistida
- Ley 25.326 — Protección de los datos personales
- Escuela de la Defensa Pública — BER (Causa N° 64827), 27 November 2025
- Poder Judicial de Neuquén — gestación por sustitución y artículo 562, 15 October 2026
This material is general legal information, not individual medical advice or a legal opinion.
